For the tissue samples from patients with clinical outcomes, the KM analysis indicated that HCC patients with a relatively lower expression of TARBP2 had a worse three-year OS (Figure 1C; log rank p-value = 0.005). Here, TARBP2 is linked to hepatocellular carcinoma.